 |
15 Diseases |  |
1 Trial |
|
1 Trial |  |
30 News |  |
- | granisetron oral / Generic mfg.
New trial: Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group (clinicaltrials.gov) - Dec 19, 2023
P=N/A, N=160, Completed, Sponsor: Ain Shams University
- | Trial completion, Trial completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Sep 23, 2021
P3, N=120, Completed, Sponsor: Stanford University
Recruiting --> Completed | Trial completion date: Mar 2020 --> Jun 2021
- || Trial completion date, Trial primary completion date, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Aug 18, 2021
P2, N=150, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Recruiting --> Completed | Trial completion date: Mar 2020 --> Jun 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
- | Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Enrollment change: Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia (clinicaltrials.gov) - Aug 13, 2021
P3, N=8, Completed, Sponsor: University of Colorado, Denver
Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021 N=85 --> 8
- Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Phase classification: Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water (clinicaltrials.gov) - Aug 18, 2020
P1, N=18, Completed, Sponsor: Aquestive Therapeutics
N=85 --> 8 Phase classification: P3 --> P1
- Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Phase classification: Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets (clinicaltrials.gov) - Aug 9, 2020
P1/2, N=48, Completed, Sponsor: MonoSol Rx
Phase classification: P3 --> P1 Phase classification: P3 --> P1/2
- | Varubi (rolapitant oral) / TerSera Therap, GSK
Trial termination: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Jul 16, 2020
P2, N=37, Terminated, Sponsor: M.D. Anderson Cancer Center
Phase classification: P3 --> P1/2 Completed --> Terminated; Terminated per PI's request
- | Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Jul 14, 2020
P2, N=37, Completed, Sponsor: M.D. Anderson Cancer Center
Completed --> Terminated; Terminated per PI's request Recruiting --> Completed | N=91 --> 37 | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020
- || Trial completion date, Trial primary completion date, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Feb 12, 2020
P2, N=150, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Recruiting --> Completed | N=91 --> 37 | Trial completion date: Dec 2020 --> Jul 2020 | Trial primary completion date: Dec 2020 --> Jul 2020 Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- | NN1213 / Novo Nordisk, Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Enrollment closed, Trial completion date, Trial primary completion date: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Sep 15, 2019
P4, N=70, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Oct 2019 | Trial primary completion date: Mar 2018 --> Oct 2019
- | Varubi (rolapitant oral) / TerSera Therap, GSK
Trial primary completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Aug 14, 2019
P2, N=91, Recruiting, Sponsor: M.D. Anderson Cancer Center
Completed --> Active, not recruiting | Trial completion date: Mar 2018 --> Oct 2019 | Trial primary completion date: Mar 2018 --> Oct 2019 Trial primary completion date: Jul 2019 --> Dec 2020
- | Varubi (rolapitant oral) / TerSera Therap, GSK
Trial primary completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - May 24, 2019
P2, N=91, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2019 --> Dec 2020 Trial primary completion date: Oct 2019 --> Jul 2019
- | Varubi (rolapitant oral) / TerSera Therap, GSK
Trial completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - May 22, 2019
P2, N=91, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Oct 2019 --> Jul 2019 Trial completion date: Oct 2019 --> Oct 2020
- | Trial completion date, Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - May 21, 2019
P3, N=128, Recruiting, Sponsor: Stanford University
Trial completion date: Oct 2019 --> Oct 2020 Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Jan 2020
- | Trial completion date, Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Feb 11, 2019
P3, N=128, Recruiting, Sponsor: Stanford University
Trial completion date: Dec 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Jan 2020 Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Mar 2019
- | NN1213 / Novo Nordisk, Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Trial completion: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Dec 13, 2018
P4, N=70, Completed, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Jun 2018 --> Dec 2019 | Trial primary completion date: Jun 2018 --> Mar 2019 Active, not recruiting --> Completed
- | Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Phase classification: Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia (clinicaltrials.gov) - Oct 16, 2018
P3, N=85, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Phase classification: P=N/A --> P3
- | Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Enrollment closed: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Mar 20, 2018
P4, N=70, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Phase classification: P=N/A --> P3 Recruiting --> Active, not recruiting
- | Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Trial primary completion date: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Jan 26, 2018
P4, N=70, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2017 --> Feb 2018
- | Trial primary completion date: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Dec 8, 2017
P3, N=128, Recruiting, Sponsor: Stanford University
Trial primary completion date: Jan 2017 --> Feb 2018 Trial primary completion date: Nov 2017 --> Jun 2018
- || Trial primary completion date, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Nov 28, 2017
P2, N=150, Active, not recruiting, Sponsor: British Columbia Cancer Agency
Trial primary completion date: Nov 2017 --> Jun 2018 Trial primary completion date: Jul 2017 --> Dec 2018
- |||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment open, Trial initiation date, Trial primary completion date: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Oct 13, 2016
P2, N=91, Recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jul 2017 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jul 2019 --> Oct 2019
- ||| Varubi (rolapitant oral) / TerSera Therap, GSK
Enrollment change: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - May 23, 2016
P2, N=91, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Oct 2016 | Trial primary completion date: Jul 2019 --> Oct 2019 N=70 --> 91
- ||||| Varubi (rolapitant oral) / TerSera Therap, GSK
New P2 trial: Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - Apr 8, 2016
P2, N=70, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- ||| Enrollment closed, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Jan 25, 2016
P2, N=150, Active, not recruiting, Sponsor: British Columbia Cancer Agency
N=70 --> 91 Completed --> Active, not recruiting
- || New P3 trial: Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - Nov 10, 2015
P3, N=128, Recruiting, Sponsor: Stanford University
- NN1213 / Novo Nordisk, Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Trial completion, Trial primary completion date: Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia (clinicaltrials.gov) - Aug 13, 2015
P=N/A, N=85, Completed, Sponsor: University of Colorado, Denver
Completed --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: Feb 2009 --> May 2010
- |||| Trial completion, Metastases: LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - Jan 28, 2015
P2, N=150, Completed, Sponsor: British Columbia Cancer Agency
Recruiting --> Completed | Trial primary completion date: Feb 2009 --> May 2010 Recruiting --> Completed
- temozolomide / Generic mfg.
Enrollment change, Trial withdrawal, Trial primary completion date, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Sep 22, 2014
P2, N=0, Withdrawn, Sponsor: Duke University
Recruiting --> Completed N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2016 --> Sep 2014
- Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Trial initiation date: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Apr 29, 2014
P4, N=70, Recruiting, Sponsor: University of Texas Southwestern Medical Center
N=90 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Apr 2016 --> Sep 2014 Initiation date: Mar 2014 --> Apr 2014
- Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
Enrollment open: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Apr 29, 2014
P4, N=70, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Initiation date: Mar 2014 --> Apr 2014 Not yet recruiting --> Recruiting
- | Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine
New P4 trial: Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - Mar 6, 2014
P4, N=70, Not yet recruiting, Sponsor: University of Texas Southwestern Medical Center
- ||| temozolomide / Generic mfg.
Trial initiation date, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Mar 3, 2014
P2, N=90, Not yet recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting Initiation date: Oct 2013 --> Apr 2014
- ||||| temozolomide / Generic mfg.
New P2 trial, Compliance: Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients (clinicaltrials.gov) - Sep 26, 2013
P2, N=90, Not yet recruiting, Sponsor: Duke University